Supervivencia y efectividad del tratamiento médico – quirúrgico en adenocarcinoma de próstata según etapa clínica
Fecha
2023
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
Antecedentes: El cáncer de próstata (CP) es el segundo cáncer más común en hombres alrededor del mundo. Su supervivencia está condicionada a un adecuado tamizaje, estadificación y tratamientos oportunos. No existían investigaciones locales que validen la efectividad de las intervenciones clínicos quirúrgicos disponibles para esta enfermedad en nuestro medio. Metodología: Se realizó un estudio caso control, que incluyó 303 pacientes consecutivos con CP, elegidos sin aleatorización, atendidos en el Hospital Teodoro Maldonado entre el 01/08/2015 y 30/04/2021, que fueron sometidos a tratamiento clínico-quirúrgico en esta institución. Se construyeron tablas de Kaplan Meier tomando como punto final la mortalidad y recurrencia. Los tiempos de sobrevida y el tiempo libre de recurrencia se comparó mediante la prueba de Log Rank y se consideró significativo una p < 0.05 Resultados: La edad promedio fue 67 ± 10 años, recayeron 31 (10%) y murieron 137 (45.2%). La media de sobrevida fue la siguiente: Estadio I, 50 meses (IC95% 42-58); Estadio II, 46 meses (IC95% 42-58); Estadio III, 51 meses (IC95% 46-55); Estadio IV, 33 meses (IC95% 30-37); Global, 42 meses (IC95% 40-45) existiendo una diferencia estadística (p < 0.001). La media de tiempo libre de recurrencia fue: Estadio I, no hubo; Estadio II, 54 meses (IC95% 50-58); Estadio III, 58 meses (IC95% 56-60); Estadio IV, 56 meses (IC95% 53-59); Global, 42 meses (IC95% 4044) existiendo una diferencia estadística (p < 0.05). Conclusiones: Existen diferencias en la efectividad (sobrevida y tiempo libre de recurrencia) en pacientes con CP estadio IV.
Background: Prostate cancer (PC) is the second most common cancer in men worldwide. Its survival is conditioned by adequate screening, staging and timely treatment. No local investigations have validated the effectiveness of clinicalsurgical interventions available for this disease in our setting. Methodology: A case-control study was conducted, which included 303 consecutive patients with PC, chosen without randomization, treated at the Teodoro Maldonado Hospital between 08/01/2015 and 04/30/2021, who underwent clinical-surgical treatment in this institution. Kaplan-Meier curves were performed, taking mortality and relapse as the endpoint. The Log Rank test compared survival times and relapse-free time, and p < 0.05 was considered significant. Results: The average age was 67 ± 10 years. 31 (10%) relapsed, and 137 (45.2%) died. Mean survival was as follows: Stage I, 50 months (95% CI 42-58); Stage II, 46 months (95% CI 42-58); Stage III, 51 months (95% CI 46-55); Stage IV, 33 months (95% CI 30-37); Global, 42 months (CI95% 40-45) with a statistical difference (p < 0.001). The mean relapse-free time was Stage I, none; Stage II, 54 months (95% CI 50-58); Stage III, 58 months (95% CI 56-60); Stage IV, 56 months (95% CI 53-59); Global, 42 months (CI95% 40-44) with a statistical difference (p < 0.05). Conclusions: There are differences in effectiveness (survival and relapse-free time) in patients with stage IV PC
Background: Prostate cancer (PC) is the second most common cancer in men worldwide. Its survival is conditioned by adequate screening, staging and timely treatment. No local investigations have validated the effectiveness of clinicalsurgical interventions available for this disease in our setting. Methodology: A case-control study was conducted, which included 303 consecutive patients with PC, chosen without randomization, treated at the Teodoro Maldonado Hospital between 08/01/2015 and 04/30/2021, who underwent clinical-surgical treatment in this institution. Kaplan-Meier curves were performed, taking mortality and relapse as the endpoint. The Log Rank test compared survival times and relapse-free time, and p < 0.05 was considered significant. Results: The average age was 67 ± 10 years. 31 (10%) relapsed, and 137 (45.2%) died. Mean survival was as follows: Stage I, 50 months (95% CI 42-58); Stage II, 46 months (95% CI 42-58); Stage III, 51 months (95% CI 46-55); Stage IV, 33 months (95% CI 30-37); Global, 42 months (CI95% 40-45) with a statistical difference (p < 0.001). The mean relapse-free time was Stage I, none; Stage II, 54 months (95% CI 50-58); Stage III, 58 months (95% CI 56-60); Stage IV, 56 months (95% CI 53-59); Global, 42 months (CI95% 40-44) with a statistical difference (p < 0.05). Conclusions: There are differences in effectiveness (survival and relapse-free time) in patients with stage IV PC
Descripción
PDF
Palabras clave
NEOPLASIAS DE LA PROSTATA, HOMBRES, CALIDAD DE VIDA, HOSPITAL DE ESPECIALIDADES DR. TEODORO MALDONADO CARBO, CANTON GUAYAQUIL, ECUADOR, TRATAMIENTO QUIRURGICO